The role of international organisations in the elimination of viral hepatitis in Europe – Achievements, challenges and the way forward (5-6 April 2023, Antwerp, Belgium)

Meeting Objectives:

  • Provide an overview of the current viral hepatitis situation in Europe, in relation to the renewed WHO global health sector strategies 2022-2030
  • Discuss initiatives, achievements, best practices and challenges from international organizations in the prevention and control of viral hepatitis
  • Assess the needs to achieve elimination of viral hepatitis as a major public health threat by 2030 as set out in the new WHO Global Health Sector Strategies 2022-2030
  • Investigate potential collaborations
  • Discuss successes, good practices, issues and barriers to overcome and the way forward.


Background document (PDF, 702 kB)

Wednesday 5 April 2023 – Part 1


Chairs: Pierre Van Damme and Angela Dominguez

Welcome and opening of the meeting

  • Welcome and opening 
  • Introduction of the participants


Session 1.1: WHO elimination goals – setting the scene


History of Global and European efforts to control Hepatitis B (pdf, 0.651Mb)

Mark Kane


Current situation & the new WHO Global Health Sector Strategies 2022-2030 (pdf, 5.737 Mb)

Philippa Easterbrook, WHO HQ (ONLINE)


How to apply the WHO Global Health Sector Strategies in Europe? (pdf, 2.657 Mb)

Marcelo Naveira, WHO Euro



Q&A and identify most important barriers

COFFEE BREAK 10:40-11:10


Session 1.2: Major barriers to overcome

Chairs: Vladimir Chulanov and Silvia Bino

ETAGE Working Group on Hepatitis B and progress of countries of the WHO European Region towards validation of hepatitis B control targets (pdf, 1.642 Mb)

Sandra Dudareva


Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? (2020) (pdf, 1.048 Mb)

Graham Cooke


Survey results on the progress toward the WHO viral hepatitis elimination goals (pdf, 1.230 Mb)

Kate Turpie

12:00-12:10 Q&A and barriers to add


Session 1.3: Role of international organisations (Part 1)


European Centre for Disease Prevention and Control (ECDC) (pdf, 1.994 Mb)

Erika Duffell, ECDC

Centers for Disease Control and Prevention (CDC) (pdf, 1.145 Mb)

Senad Handanagic, CDC (ONLINE)

12:50-13:00 Q&A and barriers to add

LUNCH BREAK 13:00-14:00


Session 1.4: Role of International organisations (part 2)

Chairs: Maria Buti and Daniel Lavanchy

International Viral Hepatitis Elimination Meeting (IVEM) & The Task Force for Global Health – Coalition for Global Hepatitis Elimination (pdf, 466.201 Mb)

John Ward

Q&A and barriers to add


Session 1.5: Actions taken by patient organisations


World Hepatitis Alliance (WHA) (pdf, 1.675 Mb)

Cary James

European Liver Patients’ Association (ELPA) (pdf, 3.072 Mb)

Ivana Dragojević

Liver Patients International (LPI) (pdf, 0.170 Mb)

José Willemse

Q&A and barriers to add

COFFEE break 15:30-16u00


Session 1.6: Role of International organisations (part 3)

Chairs: Erika Duffell and Sandra Dudareva

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (pdf, 1.080 Mb)

Thomas Seyler (ONLINE)

Correlation Network (pdf, 3.506 Mb)

Roberto Pérez Gayo

International Centre for Migration, Health and Development (ICMHD) (pdf, 0.118Mb)

Manuel Carballo

UNITE (pdf, 9.025 Mb)

Ricardo Baptista Leite (ONLINE)

Q&A and barriers to add


Session 1.7: European projects highlighted


International projects working toward the elimination goals

  1. CORE “COmmunity REsponse to End Inequalities” (pdf, 0.643 Mb)

Oksana Panochenko

  1. BOOST (pdf, 0.867 Mb)

Roberto Pérez Gayo

  1. VH-COMSAVAC (pdf, 7.129 Mb)

Camila Picchio (ONLINE)

  1. RISE-Vac (mp4, 169.579 Mb)

Lara Tavoschi (PRE-RECORDED)


EU initiatives focusing on hepatitis (pdf, 0.953 Mb)

Katharina Ossenberg (ONLINE)


Ranking the identified barriers – general discussion

Organisations indicate which barriers they can help to overcome.

DINNER at 19:30


Thursday 6 April 2023 – Part 2

Session 2.1: Role of International organisations (part 4)

Chairs: Marcelo Naveira and Françoise Roudot-Thoraval

Center for Disease Analysis (CDA) (pdf, 2.190 Mb)

Devin Razavi-Shearer & Sarah Blach

European Society for Clinical Virology (ESCV) (pdf, 1.164 Mb)

Xavier López Labrador


European Association for the Study of the Liver (EASL) (pdf, 5.184 Mb)

Maria Buti


Associations Collaborating on Hepatitis to Immunise and Eliminate the Viruses in Europe (ACHIEVE) (pdf, 1.765 Mb)

Katharina Ossenberg (ONLINE)

10:00-10:20 Q&A and barriers to add

COFFEE break 10:20-11:00


Session 2.2: Groups discussions

Chairs: John Ward

Ranking the identified barriers – groups discussions 

Each group discusses how to handle one of the identified barriers, with a focus on the capacity of international organisations and how to work together better to improve the outcome.

12:00-12:30 Outcome of the groups discussions & general discussion


LUNCH 12:30-14:00 

Session 2.3: Meeting summary by David FitzSimons

Chairs: Mark Kane and Pierre Van Damme

Meeting summary (pdf, 0.211 Mb)

David FitzSimons

14:40-15:00 Closing remarks


Meeting report (375kB, Pdf) by David FitzSimons.